Seasonal influenza vaccination may mitigate the potential impact of an H5N1 pandemic

Chinese Medical Journal

Volumn 121, Issue 15, 2008, Pages 1481-1483

  Qin, Cheng Feng ^a   Qin, E De ^a  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

Author keywords

Cross protection; Influenza A virus; Neuraminidase; Pandemic vaccine

Indexed keywords

ADENOVIRUS VECTOR; DNA VACCINE; INFLUENZA VACCINE;

ARTICLE; AVIAN INFLUENZA; DISEASE SEVERITY; ENDEMIC DISEASE; HEALTH PROGRAM; HUMAN; INFECTION CONTROL; INFECTION PREVENTION; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A H5N1; NONHUMAN; PANDEMIC; VIRUS IMMUNITY;

EID: 51349128619     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00029330-200808010-00027     Document Type: Article

References (19)

1. Brankston G, Gitterman L, Hirji Z, Lemieux C, Gardam M. Transmission of influenza A in human beings. Lancet Infect Dis 2007; 7: 257-265.
2. World Health Organization. Cumulative number of confirmed human cases of avian influenza A/(H5N1) reported to WHO. (Accessed November 12, 2007 at: http://www.who.int/csr/disease/avian_influenza/country/ cases_table_2007_11_12/en/index.html.)
3. Stöhr K, Esveld M. Public health. Will vaccines be available for the next influenza pandemic? Science 2004; 306: 2195-2196.
4. Poland GA. Vaccines against avian influenza - a race against time. N Engl J Med 2006; 354: 1411-1413.
5. Bresson JL, Perronne C, Launay O, Gerdil C, Saville M, Wood J, et al. Safety and immunogenicity of an inactivated split-virion influenza A/ Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 2006; 367: 1657-1664.
6. Nicholson KG, Colegate AE, Podda A, Stephenson I, Wood J, Ypma E, et al. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 2001; 357: 1937-1943.
7. Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 2006; 354: 1343-1351.
8. Johansson BE, Matthews JT, Kilbourne ED. Supplementation of conventional influenza A vaccine with purified viral neuraminidase results in a balanced and broadened immune response. Vaccine 1998; 16: 1009-1015.
9. Johansson BE, Kilbourne ED. Comparative long-term effects in a mouse model system of influenza whole virus and purified neuraminidase vaccines followed by sequential infections. J Infect Dis 1990; 162: 800-809.
10. Hocart M, Grajower B, Donabedian A, Pokorny B, Whitaker C, Kilbourne ED. Preparation and characterization of a purified influenza virus neuraminidase vaccine. Vaccine 1995; 13: 1793-1798.
11. Chen Z, Kadowaki S, Hagiwara Y, Yoshikawa T, Matsuo K, Kurata T, et al. Cross-protection against a lethal influenza virus infection by DNA vaccine to neuraminidase. Vaccine 2000; 18: 3214-3222.
12. Sandbulte MR, Jimenez GS, Boon AC, Smith LR, Treanor JJ, Webby RJ. Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans. PLoS Med 2007; 4: e59.
13. Kilbourne ED. Influenza pandemics of the 20th century. Emerg Infect Dis 2006; 12: 9-14.
14. Kilbourne ED. Influenza pandemics: can we prepare for the unpredictable? Viral Immunol 2004; 17: 350-357.
15. Beigel JH, Farrar J, Han AM, Hayden FG, Hyer R, de Jong MD, et al. Avian influenza A (H5N1) infection in humans. N Engl J Med 2005; 353: 1374-1385.
16. Lu JH, Zhang DM, Wang GL. Highlight the significance of genetic evolution of H5N1 avian flu. Chin Med J 2006; 119: 1458-1464.
17. Chen Z. Influenza DNA vaccine: an update. Chin Med J 2004; 117: 125-132.
18. Hoelscher MA, Garg S, Bangari DS, Belser JA, Lu X, Stephenson I, et al. Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice. Lancet 2006; 367: 475-481.
19. Palese P. Making better influenza virus vaccines. Emerg Infect Dis 2006; 12: 61-65.